Mindfulness Medication

  Hey team, Lately, I’ve been deep into behavioral economics, especially the work of Daniel Kahneman, which highlights the consistent irrationalities in human decision-making. These patterns, while irrational, are often predictable, and nowhere are they more visible (or more costly) than in healthcare. My interest in this stems from a broader curiosity about human behavior, how we often make decisions that seem illogical on the surface, yet follow systematic patterns that can be understood, anticipated, and even shaped to support better outcomes. Today, I want to explore one piece of that puzzle: expectancy. Specifically, how it shapes our experience of medical treatment, including both its beneficial effects and trade-offs. I'll be organizing this around four key questions: ...

  Healthcare is full of decisions, but if we think we’re making them rationally, we’re fooling ourselves. Humans are capable of great rationality, as demonstrated by progress in nearly every facet of life , yet we are predominantly irrational far more of the time. We fall into simple traps guided by gut feelings, group affiliation, inertia, and other cognitive shortcuts. After all, carefully weighing every option for potential benefit and harm is not only impractical — it's exhausting. We humans are seldom pure rational actors. Here, I want to briefly lay out Prospect Theory as an alternative model to the traditional “rational choice” view, and show how it directly applies to healthcare. Among its key ideas: we fear losses more than we value gains, we distort probabilities, and we judge outcomes relative to a reference point, not in absolute terms. That’s why gaining ...

  Framing is the phenomenon where our perception of a choice changes depending on how the information is presented, even when the underlying facts are the same. Imagine a new drug for hypertension. In clinical trials, it lowered blood pressure to a healthy level in 90% of patients. We could say: "This drug is 90% effective!" and it would be seen as a triumph. But we could just as accurately say: "It fails to work in 1 out of every 10 patients." Suddenly, that same drug seems a little less impressive. Nothing about the data changed—only the story around it. This effect extends well beyond numbers. Take side effects: we could frame them as "most people experience none," or as "a significant minority do." Both are technically true. But the emotional and clinical weight those statements carry i...

  I am beyond happy and extremely grateful for my recent teams victory of the ACCP clinical research challenge. Beyond our win I care far more about the real problem we sought to address. This project started with my own passion for psychiatry, including the complexities of not only psychopharmacologic modalities of care, but the nuances I'm doing it right. Like a growing number of people, especially young adults, I was once prescribed antidepressants. When the time came to discontinue them under my provider’s guidance, I faced severe withdrawal symptoms that lasted for months. It was one of the most painful experiences of my life, and, critically, I’m far from alone. Antidepressants remain among the most commonly prescribed drug classes worldwide, a trend that continues to rise, especially among younger populations. In...